Although idiosyncratic adverse drug reactions are rare, they are still a major concern to
patient safety. Reactive metabolites are widely accepted as playing a pivotal role in the …

Drug‐induced liver injury (DILI) is a significant leading cause of hepatic dysfunction, drug
failure during clinical trials and post‐market withdrawal of approved drugs. Many cases of …

Most small-molecule drug candidates fail before entering the market, frequently because of
unexpected toxicity. Often, toxicity is detected only late in drug development, because many …

Selective and sensitive detection of toxic cyanide (CN−) by a post‐synthetically altered metal–
organic framework (MOF) has been achieved. A post‐synthetic modification was employed …

Ponatinib (PNT), as a multi-targeted tyrosine kinase inhibitor, is active against T315I and
other BCR-ABL mutants. PNT is registered in the US and EU under the trade name of …

The success of in silico, in vitro, and in vivo methods for DNA‐damaging carcinogens
detection highlights the need to understand the mechanisms by which reactive metabolite …

Understanding the metabolic fate of drug candidates in vitro and in vivo is a key component
of drug development. Structural characterisation of drug candidate metabolites is important …